Hi ,

ICYMI: Join us in welcoming our Chairs of the SynBioBeta 2025 Tools & Technologies track! These leaders will spearhead key discussions on the latest innovations in synthetic biology, exploring how groundbreaking tools are transforming research and healthcare. 

Latest Videos From SynBioBeta 2024:

• Bridging Biology and AI for Genome Design. Check this presentation from Patrick Hsu, co-founder of the Arc Institute and a professor at UC Berkeley. Patrick’s work embodies the innovative spirit necessary to tackle today's most challenging biomedical questions, and his laboratory's focus on inventing new technologies for biological programming and design is setting new standards for what is possible in the fast-moving fields of biotechnology, genetic engineering, and artificial intelligence.

Insights:

• The Influence of Synthetic Biology on National Bioeconomy Strategies: The synthetic biology industry is commonly hailed as the most promising way to advance the global bioeconomy, but how do the policymakers perceive this potential, and should they integrate it into the national bioeconomy strategies?

Industry News:

• Biomatter Raises €6.5M to Revolutionize Enzyme Design with Generative AI: With fresh funding, Biomatter aims to revolutionize enzyme creation using its Intelligent Architecture™ platform, enabling rapid innovation across multiple industries.
  

• Life and Vitality in Mice Extended with New Treatment. Monthly treatments help mice live longer and maintain physical function, suggesting a potential breakthrough for human aging.

• Twist Bioscience and bitBiome Announce Transaminase Enzyme Screening Kit: The kit represents a significant advancement in biocatalysis, providing researchers and manufacturers with innovative tools to enhance efficiency and sustainability in pharmaceutical synthesis.

• How Phages Infect Bacteria: Latest Research Uncovers Crucial Details. A new study used advanced techniques to show that the cell's electrophysiology influences phage entry.

• Primient and Synonym Forge Strategic Partnership to Propel U.S. Bioproduct Innovation. Once completed, the Primient-Synonym facility will offer a full suite of services for companies utilizing precision fermentation, enabling them to scale new product concepts from the lab to commercial production.

• Molecular Devices Unveils QPix Insights to Transform Microbial Colony Analysis: QPix Insights enables advanced data analytics and visualization for informed colony selection strategies.

Additional Industry News:

• Senti Bio Announces Execution of Grant Award from California Institute for Regenerative Medicines (CIRM) for Clinical Development of SENTI-202 (Press release)

• The inaugural episode of The Biotech Startups Podcast is live! Host Jon Chee, CEO of Excedr, is joined by Jake Glanville, founder and CEO of Centivax! (Apple Podcasts)

• Integrated DNA Technologies Bolsters Synthetic Biology Portfolio with Launch of Rapid Genes and Significant Upgrades to Gene Synthesis Offerings (Press release)

• Gene-editing drugs are moving from lab to clinic at lightning speed. The promising treatments still face technical and economic hurdles, though. (The Economist)

• Synthetic Biology at Scale: Less Disruption, More Cohesion. For synthetic biology companies, scaling up means reaching out—working with government bodies, identifying partners, and securing manufacturing capacity (GEN)

• Algae transformed into a 'biofactory' for green fuel and plastics: A strain of green algae has been artificially evolved to turn carbon dioxide into sustainable fuel and plastic (New Scientist)

• DOD Releases Five Awards for Distributed Bioindustrial Manufacturing Program: The awardees include ARCTOS Technology Solutions in Beavercreek, Ohio; CleanJoule in Salt Lake City; Lygos in Berkeley, California; Synonym in New York City; and Visolis in Hayward, California. (Press release)

• Engineering biology is expected to disrupt all industries: Capgemini Research Institute’s latest report on the bioeconomy, “Engineering biology: The time is now,” finds that sustainability is a major driver of corporate interest, with over 70% of organizations expecting biosolutions to significantly accelerate their progress towards sustainability goals.

Regards,

Jeff

Jeffrey S. Buguliskis, PhD

Director of Content, SynBioBeta

Who's hiring?

• Science Manager & Carbon Capture Venture Tech Lead at Novonesis (Lyngby, Denmark)

• Chief of Staff to COO at Maverick BioMetals (San Antonio, TX)

• Head of Informatics at Colorifix (Norwich or Cambridge)

• Centre Manager at Bezos Centre for Sustainable Protein (London, UK)

• Head of Growth, Innovation, and Impact at Bezos Centre for Sustainable Protein (London, UK)

• Communications and Marketing Lead at Bezos Centre for Sustainable Protein (London, UK)

• Lecturer/Senior Lecturer/Reader/Professor at Bezos Centre for Sustainable Protein (London, UK)